PDF DatasheetHuman Anti-Protocadherin FAT2 Antibody Product Attributes
Protocadherin FAT2 Previously Observed Antibody Staining Patterns
Observed Antibody Staining Data By Tissue Type:
Variations in Protocadherin FAT2 antibody staining intensity in immunohistochemistry on tissue sections are present across different anatomical locations. An intense signal was observed in cells in the granular layer in cerebellum, epidermal cells in the skin, squamous epithelial cells in the cervix and uterine, tonsil and vagina. More moderate antibody staining intensity was present in cells in the granular layer in cerebellum, epidermal cells in the skin, squamous epithelial cells in the cervix and uterine, tonsil and vagina. Low, but measureable presence of Protocadherin FAT2 could be seen inkeratinocytes in skin. We were unable to detect Protocadherin FAT2 in other tissues. Disease states, inflammation, and other physiological changes can have a substantial impact on antibody staining patterns. These measurements were all taken in tissues deemed normal or from patients without known disease.
Observed Antibody Staining Data By Tissue Disease Status:
Tissues from cancer patients, for instance, have their own distinct pattern of Protocadherin FAT2 expression as measured by anti-Protocadherin FAT2 antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
| Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal Intensity | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | + |
| FAT2 Variability | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | ++ |
| Protocadherin FAT2 General Information | |
|---|---|
| Alternate Names | |
| FAT2, FAT atypical cadherin 2 | |
| Molecular Weight | |
| 480kDa | |
| Chromosomal Location | |
| 5q33.1 | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | FAT2 |
| Entrez Gene ID | 2196 |
| Ensemble Gene ID | ENSG00000086570 |
| RefSeq Protein Accession(s) | XP_011535905, XP_006714824, XP_016864714, XP_016864715, XP_016864716, NP_001438, XP_011535902, XP_016864713 |
| RefSeq mRNA Accession(s) | XM_006714761, XM_011537603, XM_017009227, XM_017009224, XM_017009225, XR_001742039, XR_001742040, NM_001447, XM_011537600 |
| RefSeq Genomic Accession(s) | NG_046979, NC_000005, NC_018916 |
| UniProt ID(s) | Q9NYQ8, Q6PIA2 |
| UniGene ID(s) | Q9NYQ8, Q6PIA2 |
| HGNC ID(s) | 3596 |
| Cosmic ID(s) | FAT2 |
| KEGG Gene ID(s) | hsa:2196 |
| PharmGKB ID(s) | PA28009 |
| General Description of Protocadherin FAT2. | |
| Recognizes a protein of 480kDa, which is identified as FAT2. The cadherins represent a family of Ca2+-dependent adhesion molecules that function to mediate cell-to-cell binding that is critical for the maintenance of structure and morphogenesis. Cadherins each contain a large extracellular domain at the N-terminus, which is characterized by a series of five homologous repeats, the most distal of which is thought to be responsible for binding specificity. The relatively short C-terminal intracellular domain interacts with a variety of cytoplasmic proteins, including ?-catenin, to regulate cadherin function. The cadherin superfamily includes cadherins, protocadherins, desmogleins and desmocollins. FAT2 (FAT tumor suppressor homolog 2) is a single-pass type I membrane protein that belongs to the protocadherin subfamily of cadherins. FAT2 contains one Laminin G-like domain, two EGF-like domains and 32 cadherin domains and is believed to function as a cell adhesion molecule, controlling cell proliferation and playing an important role in cerebellum development. | |
There are no reviews yet.